The mechanism, side by side
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, an incretin hormone the gut releases after eating — slowing gastric emptying, prompting insulin release when glucose is high, and signaling satiety in the hypothalamus.
Tirzepatide is a dual agonist: it activates the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is a second incretin. The working hypothesis is that engaging both pathways produces additive metabolic effects — greater insulin sensitivity and, in the trials, greater weight loss — than GLP-1 alone.
What the head-to-head data shows
The SURPASS-2 trial compared tirzepatide directly against semaglutide in type 2 diabetes and found greater HbA1c and weight reductions across tirzepatide's dose range. In obesity, the STEP program (semaglutide) and SURMOUNT program (tirzepatide) were run separately, but the mean weight reductions reported for tirzepatide's higher doses exceeded those reported for semaglutide.
The honest caveat: cross-trial comparison is not a head-to-head. Populations, durations, and titration schedules differ. What is well established is that both produce clinically meaningful weight and glycemic effects, and that tirzepatide's readouts trend higher.
| Semaglutide | Tirzepatide | |
|---|---|---|
| Targets | GLP-1 receptor | GLP-1 + GIP receptors |
| Class | Single incretin agonist | Dual incretin agonist |
| Dosing | Weekly SC, titrated | Weekly SC, titrated |
| Trial weight effect | Substantial | Substantial → greater at higher doses |
| Titration | Slow, to limit GI effects | Slow, to limit GI effects |
The side-effect curve
Both drugs share the same dominant side effects: nausea, and gastrointestinal upset that is worst during dose escalation and settles as the body adapts. This is why both are titrated slowly — starting low and stepping up over weeks — rather than started at the effective dose.
The more potent the metabolic effect, the more carefully titration matters. Neither is a drug you self-escalate. A physician sets the schedule against how you tolerate each step, and holds or steps back when the GI burden is too high.
How a physician chooses
The choice is not 'which is stronger' but 'which fits this patient.' It weighs the metabolic target, prior response to a GLP-1, tolerance of GI side effects, contraindications, and — for compounded formulations — what is appropriate and available in your state.
Both are prescription-only. Both are contraindicated in personal or family history of medullary thyroid carcinoma or MEN 2, and in pregnancy. At Nexphoria, the metabolic route is gated behind intake and bloodwork; a physician selects the molecule and the titration, and can decline. This article is educational, not a recommendation of one over the other.
Bottom line
Semaglutide engages one incretin pathway; tirzepatide engages two, and the trial data trend accordingly. But the deciding factors in practice are fit and tolerance, not a leaderboard. The right answer is the one a physician reaches with your labs in front of them.
Share
References
- [1]Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. Link
- [2]Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. Link
- [3]Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002. Link